<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Receptor-targeted therapies have become standard in the treatment of various <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In view of its unparalleled specificity for the malignant B-cell clone, the B-cell receptor (BCR) on B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells is a potential therapeutic target </plain></SENT>
<SENT sid="2" pm="."><plain>We have used two BCR <z:chebi fb="0" ids="53000">epitope</z:chebi> mimicking <z:chebi fb="7" ids="16670">peptides</z:chebi> binding to the Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines CA46 and SUP-B8 </plain></SENT>
<SENT sid="3" pm="."><plain>We proved their functionality by demonstrating calcium flux and BCR-mediated endocytosis upon <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor binding </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicity experiments in vitro via cross-linking of the BCR with tetramerized <z:chebi fb="0" ids="53000">epitope</z:chebi> mimics lead to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in both cell lines but was far more effective in SUP-B8 cells </plain></SENT>
<SENT sid="5" pm="."><plain>We established a SUP-B8-based disseminated Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> model in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing mice with tetramerized <z:chebi fb="0" ids="53000">epitope</z:chebi> mimics had significant anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effects in vivo </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that <z:chebi fb="7" ids="16670">peptide</z:chebi>-mediated, BCR-targeted therapy is a promising approach which may be explored and further developed for application in highly aggressive <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>